SAMANTHA THOMAS: Open Payments
NPI 1417551169 · EASTVALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 17 payments from 8 companies in 2025. Trend: 2023 $674 · 2024 $205 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $247 |
| Otsuka America Pharmaceutical, Inc. | 3 | $171 |
| Novo Nordisk Inc | 1 | $131 |
| E.R. Squibb & Sons, L.L.C. | 3 | $123 |
| Teva Pharmaceuticals USA, Inc. | 4 | $96 |
| Lilly USA, LLC | 1 | $60 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
| Alkermes, Inc. | 1 | $19 |
Products named: VRAYLAR, REXULTI, Wegovy, COBENFY, AUSTEDO XR, ZEPBOUND, INGREZZA, UZEDY.
Industry payments across CA — which companies pay providers there.
